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Chromatin remodeling protein HELLS is critical for
retinoblastoma tumor initiation and progression
Loredana Zocchi1, Aditi Mehta2,3, Stephanie C. Wu4, Jie Wu5,6, Yijun Gu1, Jingtian Wang7, Susie Suh8,
Robert C. Spitale 1,7 and Claudia A. Benavente1,4,6
Abstract
Retinoblastoma is an aggressive childhood cancer of the developing retina that initiates by biallelic RB1 gene
inactivation. Tumor progression in retinoblastoma is driven by epigenetics, as retinoblastoma genomes are stable, but
the mechanism(s) that drive these epigenetic changes remain unknown. Lymphoid-speciﬁc helicase (HELLS) protein is
an epigenetic modiﬁer directly regulated by the RB/E2F pathway. In this study, we used novel genetically engineered
mouse models to investigate the role of HELLS during retinal development and tumorigenesis. Our results indicate
that Hells-null retinal progenitor cells divide, undergo cell-fate speciﬁcation, and give rise to fully laminated retinae
with minor bipolar cells defects, but normal retinal function. Despite the apparent nonessential role of HELLS in retinal
development, failure to transcriptionally repress Hells during retinal terminal differentiation due to retinoblastoma (RB)
family loss signiﬁcantly contributes to retinal tumorigenesis. Loss of HELLS drastically reduced ectopic division of
differentiating cells in Rb1/p107-null retinae, signiﬁcantly decreased the incidence of retinoblastoma, delayed tumor
progression, and increased overall survival. Despite its role in heterochromatin formation, we found no evidence that
Hells loss directly affected chromatin accessibility in the retina but functioned as transcriptional co-activator of E2F3,
decreasing expression of cell cycle genes. We propose that HELLS is a critical downstream mediator of E2F-dependent
ectopic proliferation in RB-null retinae. Together with the nontoxic effect of HELLS loss in the developing retina, our
results suggest that HELLS and its downstream pathways could serve as potential therapeutic targets for
retinoblastoma.
Introduction
The RB pathway can directly regulate genes that control
cell cycle exit but can also regulate the expression of genes
that control cell-fate speciﬁcation and differentiation
through mechanisms, including chromatin remodeling
and epigenetic control1. In the developing retina, the RB
pathway is critical in development and tumorigenesis.
Genetic ablation of RB is characterized by alterations in
ganglion cell, bipolar, and rod photoreceptor terminal
differentiation that results in cell death of these retinal
cells and disruption of horizontal cell synaptogenesis2,3.
Further, almost all retinoblastomas have RB1 gene inac-
tivation4,5. While genetic alterations in the RB1 gene are
required for tumor initiation, retinoblastoma tumors have
stable genomes, with tumor progression occurring
through epigenetic dysregulation of several cancer
pathways6.
HELLS (helicase, lymphoid speciﬁc; also known as LSH,
ICF4, PASG, and SMARCA6), a gene transcriptionally
controlled by the RB/E2F pathway7–9, encodes a chro-
matin remodeling protein thought to be responsible for
the epigenetic changes seen in retinoblastoma and
required for tumor survival10. HELLS is a SWI/SNF-
related matrix-associated regulator of chromatin that
contributes to global genome methylation11. HELLS
remodels chromatin to render DNA accessible to DNA
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methyltransferase enzymes Dnmt3a or Dnmt3b, sup-
porting de novo DNA methylation and stable gene
silencing during cellular differentiation12,13. Binding of
HELLS to DNMT1, HDAC1, and HDAC2 has also been
reported14. HELLS plays an important role in normal
development as HELLS knockout mice display perinatal
lethality15. Furthermore, HELLS mutant mice exhibit
signs of growth retardation, premature aging, and
impaired neural stem/progenitor cells self-renewal and
maintenance during development16,17. Thus, considera-
tion of HELLS as a therapeutic target in the treatment of
cancers requires careful consideration of the potential
toxicities that could arise in tissues exposed to treatment.
The vertebrate neural retina is organized with remark-
able precision into laminar structure formed by multiple
types of neurons and glial cells. In mouse retina, the seven
major retinal cell types (rod and cone photoreceptors;
horizontal, amacrine, and bipolar interneurons; Müller
glia; and ganglion cells) are differentiated from a common
population of multipotent retinal progenitor cells (RPCs)
that appear between embryonic day 11 (E11) and post-
natal day 10 (P10) in a conserved temporal order (Fig.
1a)18,19. The process of self-renewal and differentiation
required for RPCs to differentiate into the distinct neural
lineages is regulated by various molecular mechanisms,
including transcriptional and post-transcriptional
regulation. Epigenetic regulation plays a fundamental role
in the maintenance of cell identity as well as the stepwise
control toward cellular differentiation. Chromatin states
of RPCs change gradually during this process and
alterations of epigenetic markers during retinal develop-
ment have been linked to several ocular diseases,
including retinoblastoma6,10,20–23. Thus, understanding
the molecular mechanism and identifying key chromatin
factors that regulate retinal stem cell maintenance and
neurogenesis is critical for understanding normal retinal
development and discovering molecular pathways that
could be targeted for cancer therapy and intraocular
delivery.
To investigate the role of HELLS in normal retinal
development and tumorigenesis, we generated a series of
genetically engineered mouse models. Using a Hells
conditional knockout mouse model driven by Chx10-cre
recombinase, our results demonstrate that Hells-null
RPCs divide, undergo cell-fate speciﬁcation, and give rise
to normally laminated retinae with all seven major retinal
cell types present in normal ratios. While minor synap-
togenesis defects were observed in a subset of bipolar
cells, retinal function is unaltered in the absence of
HELLS. Despite the apparent dispensable role of HELLS
in retinal development, here we present evidence that loss
of HELLS signiﬁcantly decreases the incidence of
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Fig. 1 HELLS is repressed during the late stages of retinal development. a Illustration of the developmental stages and speciﬁcation timing of
the seven major retinal cell types: retinal ganglion cells, amacrine, horizontal, bipolar, Müller, cone, and rod photoreceptors. b Time course of Hells
mRNA expression in the developing retina in wild-type mice. Levels of Hells mRNA were measured by RT-qPCR and normalized to the levels at E15.5
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retinoblastoma, delays tumor progression, and increases
overall survival.
Results
Hells is expressed during retinal development, and
repressed following terminal differentiation
We ﬁrst investigated the normal expression pattern of
HELLS in developing retinae. Real-time reverse tran-
scriptase PCR (RT-qPCR) analysis of retinal tissue at
different developmental stages showed that Hells mRNA
is robustly expressed starting at early stages of retinal
development (E15.5), reaching its maximal expression
around postnatal day 0 (P0) and then gradually declining
until it reaches its minimal expression after P6, and is
maintained at low levels thereafter (Fig. 1b). The mRNA
levels correlate with HELLS protein expression, with high
expression of HELLS protein during the proliferative
stages of retinal development (E15.5-P2), followed by a
steep decrease that falls under the limits of detection after
retinal cell-fate speciﬁcation has been completed at P6
(Fig. 1c, d). The expression pattern of HELLS in the
developing retina suggests that HELLS is expressed from
an early stage of retinogenesis and likely required during
cell-fate speciﬁcation and differentiation.
Hells is nonessential for normal retinal development
To elucidate the function of HELLS during retinal
development, we generated genetically engineered mice to
ablate the Hells gene (Fig. 2a) in early retinal progenitors
using the Chx10-Cre allele (Chx10-Cre; Hellslox/lox; refer-
red hereafter as Hells cKO). The Hells cKO mouse model
used in this study targets exon 12, which contains the
conserved helicase domain IV. Since Chx10-Cre is
expressed in a mosaic pattern in progenitor cells, we
generated mice that also carry the Z/EG transgene to
serve as a reporter for Cre recombination. Retinal cells
that arise from the early progenitor cells that stochasti-
cally expressed Cre recombinase during early develop-
ment will express enhanced green ﬂuorescent protein
(EGFP). Western blot analysis using P0 retinae, the
postnatal stage with highest HELLS expression in wild-
type retinae, conﬁrmed a signiﬁcant twofold reduction in
HELLS protein levels in retinae expressing Chx10-Cre
compared with Cre-negative littermate controls (Fig. 2b).
A short form of HELLS protein was not observed using a
rabbit antibody against the N-terminal sequence of
HELLS, suggesting that truncated HELLS protein is not
stable or below limit of detection. As mentioned, Chx10-
Cre is expressed stochastically, therefore complete abro-
gation of protein expression was not expected when using
whole retinae.
RT-qPCR analysis of the expression of retinal cell
markers speciﬁc for the seven major retinal cell types
using ﬂow cytometry sorted EGFP+ retinal cells from
P21 retinae showed no signiﬁcant differences in the
expression of Arr3, Calb1, Chx10, Crx, GS, Hes1, Lhx1,
Nr2e3, Pax6, Prkca, Prox1, Rcvrn, and Rho in Hells cKO
retinae compared with Cre-negative littermate controls,
suggesting normal retinal differentiation in the absence of
HELLS (Fig. 2c).
Further evaluation of potential alterations in the
development of the retina upon loss of HELLS was
achieved by examining retinae cross-sections using
immunohistochemistry (Fig. 2d; Supplementary Fig. 1)
and immunocytochemistry of dissociated retinae (Fig. 2e;
Supplementary Figs. 2 and 3). We performed immunos-
taining using seven different speciﬁc antibodies against
each major retinal cell type. Hells cKO displayed no major
alterations in retinal cell birthing and cell-fate speciﬁca-
tion as evidenced by the uniform layer and thickness of
the outer nuclear layer (ONL), inner nuclear layer (INL),
and ganglion cell layer (GCL) (Fig. 2d; Supplementary Fig.
1). All cells are located in their corresponding retinal
layer. The only abnormality observed was found in a
subset of bipolar cells (Chx10-immunopositive cells). We
observed bipolar cellular processes extending through the
outer plexiform layer (OPL) into the ONL. In comparison,
the bipolar cell bodies in Cre-negative littermate controls
and in the Cre-negative areas of the same retina are
limited to the INL (Fig. 2d). No differences in spatial
localization were observed for any of the other retinal cell
types analyzed, including pkc-alpha-immunoreactive rod-
bipolar cells24 and recoverin-immunoreactive photo-
receptor cells (Fig. 2d; Supplementary Fig. 1). Immuno-
cytochemical analysis of dissociated retinae was able to
detect double-immunostained cells for every retinal cell-
type-speciﬁc antibody and the EGFP reporter of Cre
recombination (Fig. 2e; Supplementary Figs. 2 and 3).
Quantiﬁcation of EGFP+ and EGFP− cell types co-
stained with retinal cell markers indicated that all cells
are present in the correct ratios (Fig. 2f). This conﬁrms
that all retinal cell types that are born, can terminally
differentiate and survive in the absence of HELLS.
In order to determine if the aberrant bipolar processes
observed in Hells cKO mice affect normal retinal function,
we performed electroretinography (ERG) on dark-adapted
Hells cKO mice with retinae that had at least 50%
EGFP+ penetrance compared with Cre-negative litter-
mate controls (Fig. 2g, h). ERG measures the electrical
activity of the various cell types in the retina in response
to light stimulation. The a-wave hyperpolarization mea-
sures photoreceptor (cone and rod) function and the b-
wave depolarization measures the inner retinal function,
predominantly Müller and bipolar cells. Although Hells
cKO mice tend to show a lower a-wave and b-wave
amplitude, ERG recordings show neither signiﬁcant
changes in the amplitude of the a-wave, except at the
highest light intensity (Fig. 2g), nor the amplitude of the
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b-wave (Fig. 2h), consistent with the observation that
photoreceptors and inner neuron cells are comparable in
numbers between Hells cKO and littermate controls.
Hells is transcriptionally repressed by the Rb family
Previous studies have shown that HELLS is regulated
through the RB/E2F pathway and that loss of RB1 results
in upregulation and overexpression of HELLS, a process
that may contribute to epigenetic changes that drive
tumor progression7,8,10. We veriﬁed that HELLS over-
expression occurs soon after tumor initiation in Chx10-
Cre Rb1lox/lox p107−/− (Rb1/p107 DKO; Fig. 3a) retinae
and this overexpression persists in retinoblastoma tumors
(Fig. 3b). To conﬁrm that the RB/E2F pathway directly
controls Hells transcription in the retina, we performed
chromatin immunoprecipitation (ChIP) analysis using P0
wild-type and P21 Rb1/p107 DKO and Cre-negative lit-
termate control mouse retinae, as well as human retino-
blastoma tumor cells (Weri). Pull-down using an E2F1
antibody showed enrichment of E2F1 at a consensus-
binding site within the Hells promoter in samples that
highly express HELLS protein: P0 wild-type and P21 Rb1/
p107 DKO retinae and human tumor cells, but not in P21
Cre-negative Rb1/p107 (Fig. 3c).
To determine whether HELLS is transcriptionally
repressed speciﬁcally by RB or also by other members of
the RB family, we analyzed HELLS expression in Chx10-
Cre Rb1lox/lox (Rb1 cKO) and Rb1/p107 DKO retinae.
Interestingly, we found that in Rb1 cKO retinae, a mouse
model that does not develop retinoblastoma due to
compensation by p107, HELLS mRNA and protein
expression follows a similar dynamic as wild-type retinae,
with maximal expression during embryonic stages (E17.5-
P0), repression after postnatal day 2 (P2) and signiﬁcant
reduction in protein levels after postnatal day 6 (P6; Fig. 3d).
On the other hand, analysis of Rb1/p107 DKO retinae at
different stages of retinal development, alongside wild-
type littermate controls indicate an absence of HELLS
repression in Rb1/p107 DKO mice after P4, observed both
at protein (Fig. 3e, f) and transcriptional (Fig. 3g) levels.
Analysis of chromatin accessibility at the Hells locus using
ATAC-seq of P21 retinae conﬁrmed a signiﬁcant increase
in reads at the Hells promoter and along the ﬁrst two
exons in EGFP-positive (Rb−/−/p107−/−) compared with
EGFP-negative (p107−/−) ﬂow-sorted Rb/p107 DKO ret-
inal cells (Fig. 3h). Since HELLS expression levels in Rb1/
p107 DKO retinae are comparable with those observed in
wild-type retinae between E17.5 and P2 and chromatin
remains open in EGFP+ Rb/p107 DKO P21 retinal cells,
these results suggest that RB-family members are required
for Hells repression during terminal differentiation of one
or several retinal cell fates to block access of E2F1 at the
Hells promoter.
Loss of Hells reduces tumorigenesis in a genetic mouse
model of retinoblastoma
A previous study in retinoblastoma identiﬁed HELLS as
a key target gene that promotes tumor proliferation10. To
determine if HELLS overexpression is critical for retino-
blastoma development, we generated Chx10-Cre Rblox/lox
p107−/− Hellslox/lox triple knockout (Rb1/p107/Hells
TKO) mice and compared them to Rb1/p107 DKO lit-
termate controls. Rb1/p107/Hells TKO and Rb1/p107
DKO mice were followed for 1 year beginning at birth for
signs of tumor development. We found that abrogation of
Hells led to a signiﬁcant increase in survival and decreased
morbidity in Rb1/p107/Hells TKO mice compared with
their Rb1/p107 DKO littermate controls (Fig. 4a). We
observed that only 16% of Rb1/p107/Hells TKO mice
(n= 25) developed tumors compared with 72% of Rb1/
p107 DKO mice (n= 18; p < 0.0001) in the span of 1 year
(Fig. 4a). We also found that once tumors were detected,
the time to moribund status for Rb1/p107/Hells TKO
mice was on average 13.6 weeks compared to 6.8 weeks in
(see ﬁgure on previous page)
Fig. 2 Hells is nonessential for normal retinal development. a Schematic diagram of ﬂippase (Flp) removal of the neo-cassette and conditional
excision of the ﬂoxed HELLS allele. b Western blot analysis of HELLS expression in Hells cKO (Chx10-Cre Hellslox/lox) and littermate control (Hellslox/lox)
shows effective reduction of HELLS protein upon Cre recombination of ﬂoxed HELLS alleles. Actin was used as a loading control. Band intensities
were quantiﬁed by densitometry and normalized to littermate control. c RT-qPCR analysis of retinal cell marker genes. The genes of the seven major
retina cell types are proportionately expressed in EGFP+ cells from Hells cKO mice compared with cells from Cre-negative littermate controls. All data
are mean ± SD normalized to control littermates (n= 5). d Representative images of P21 retina cross-sections from Hells cKO Z/EG and littermate
control mice immunostained with chx10 (bipolar), pkc-alpha (bipolar), and recoverin (photoreceptors) antibodies (red). Retinae were double
immunostained with anti-EGFP to capture areas of Chx10-Cre-mediated EGFP expression. Nuclei were counterstained with DAPI (blue). ONL outer
nuclear layer, INL inner nuclear layer, GCL ganglion cell layer, ipl inner plexiform layer, opl outer plexiform layer. e Representative images of P21 retina
dissociated cells from Hells cKO Z/EG mice immunostained with recoverin (photoreceptors), cone arrestin (cone photoreceptors), calbindin (horizontal
and a subset of amacrine cells), chx10 (bipolar), and pkc-alpha (bipolar) antibodies (red). Cells were double immunostained with anti-EGFP to capture
areas of Chx10-Cre-mediated EGFP expression. Nuclei were counterstained with DAPI (blue). f Quantiﬁcation of the proportion of immunoreactive
cells for each cellular marker antibody shown in E and Supplementary Fig. 3 was determined for EGFP+ and EGFP− cells from Hells cKO Z/EG mice
from independent litters (n= 3). Each bar represents the mean ± SD of 500 cells scored from each retina. g, h ERGs were recorded from 5-week-old
Hells cKO (red line) and littermate control (black line). a-wave amplitude (g) and b-wave amplitude (h) were recorded at various light intensities. All
measurements are mean ± SD (n= 4).
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Rb1/p107 DKO mice (p= 0.0361; Fig. 4b). This translates
to a signiﬁcant increase of ~16 weeks in the mean survival
of tumor-bearing mice from 33.8 weeks for Rb1/p107
DKO to 49.6 weeks for Rb1/p107/Hells TKO (p= 0.0052).
We conﬁrmed that tumors arising from Rb1/p107/Hells
TKO mice had effectively recombined the conditional
Hells alleles using western blot analysis (Fig. 4c).
Tumors from Rb1/p107 DKO and Rb1/p107/Hells TKO
mice were analyzed for gene expression using RNA-seq
(n= 3 each). Surprisingly, despite the role of HELLS in
heterochromatin formation, the gene expression proﬁle
from Hells-null tumors were virtually indistinguishable
from controls, as portrayed by the PCA plot (Fig. 4d).
Comparative transcriptome analysis of tumors from Rb1/
p107 DKO and Rb1/p107/Hells TKO mice rendered only
17 signiﬁcant differential expressed genes (DEGs; Sup-
plementary Fig. 4). None of the DEGs provided insightful
information regarding the mechanism by which Hells loss
reduced the incidence of retinoblastoma or improved
survival.
Hells loss decreases cellular proliferation in Rb1/p107-
deﬁcient retinae
Since Rb1/p107/Hells TKO mice develop tumors at a
reduced frequency and with slower progression rates than
Rb1/p107 DKO mice, we aimed to identify pathways
regulated by HELLS that aid in the delayed tumor pro-
gression. Since transcriptome analysis from tumors pro-
vided limited insight, we also performed RNA-seq and
ATAC-seq analyses of P21 retinae from Rb1/p107 DKO
and Rb1/p107/Hells mice (n= 3 each) to determine if
early transcriptomic differences could deepen our
understanding of the mechanism through which Hells loss
contributes to delayed tumorigenesis.
Unlike what we found in tumors, at P21 the tran-
scriptome proﬁle of Rb1/p107/Hells TKO retinae was
markedly distinctive from Rb1/p107 DKO retinae (Fig. 5a).
None of the 17 genes identiﬁed from the tumor DEG
analysis (Supplementary Fig. 4) were differentially
expressed in the same direction in the P21 retinae DEG
analysis (data not shown). We identiﬁed a total of 1455
DEGs, with 434 upregulated genes and 1021 down-
regulated genes in Rb1/p107/Hells TKO compared with
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Rb1/p107 DKO P21 retinae. Gene ontology (GO) analysis
for biological processes of the 434 upregulated genes
show an enrichment of genes involved in visual system-
related signaling pathways and functions, as seen by the
classiﬁcation of the top ten most signiﬁcant GO terms
(Fig. 5b). Among the 1021 downregulated genes, we
observed enrichment of pathways involved in DNA
replication and cell division (Fig. 5c).
Since HELLS has a known role in heterochromatin for-
mation, we performed genome-wide analysis of chromatin
accessibility to determine which genes were differentially
expressed due to chromatin changes following loss of Hells.
For this, we used ATAC-seq to analyze EGFP+ ﬂow-sorted
Rb1/p107/Hells TKO and Rb1/p107 DKO P21 retina cells
along with EGFP- control cells. In line with our previous
ﬁndings25, Rb1/p107 DKO retinae displayed increased areas
of chromatin accessibility compared with control cells (Fig.
5d). Interestingly, Rb1/p107/Hells TKO compared with
Rb1/p107 DKO retinae showed only 22 regions of the
genome with signiﬁcant changes in chromatin accessibility,
19 of which were chromatin repression and only 3 resulting
in chromatin relaxation (Fig. 5d and data not shown).
Further, analysis of global levels of DNA methylation
assessed by dot blot using a 5-mC-speciﬁc antibody showed
no changes in genomic 5-mC levels in Rb1/p107/Hells TKO
compared with Rb1/p107 DKO and Cre-negative control
retinae (Supplementary Fig. 5). These data suggest that the
transcriptional changes observed upon Hells loss that result
in decreased tumorigenesis are likely mediated through a
mechanism independent of chromatin remodeling.
Previous in vitro studies have described HELLS as a
transcriptional co-activator of cell proliferation, binding
directly to the promoter regions of cell cycling genes,
including CDC6, MKi67, PCNA, CCNB1, MCM4, E2F1,
and CCNA226,27. Our RNA-seq analysis detected sig-
niﬁcant downregulation in all these cell cycle genes. Four
of them, E2f1, Cdc6,Mcm4, and Pcna, are part of the G1/S
transition of mitotic cell cycle cluster, our most sig-
niﬁcantly enriched GO term for downregulated genes
(Fig. 5e). Using RT-qPCR, we were able to independently
validate downregulation of these genes in Rb1/p107/Hells
TKO compared with Rb1/p107 DKO P21 retinae (Fig. 5f).
To evaluate if the transcriptional downregulation of cell
cycle genes in Rb1/p107/Hells TKO retinae results in
limited proliferation, we examined P21 retinae cross-
sections using immunohistochemistry (Fig. 5g; Supple-
mentary Fig. 6) and immunocytochemistry of dissociated
retinae (Fig. 5h) from mice injected with EdU 2 h prior to
collection. We observed a clear decrease in the number of
EdU-positive cells found along the retinae sections in
Rb1/p107/Hells TKO P21 retinae compared with Rb1/
p107 DKO (Fig. 5g; Supplementary Fig. 6). We quantiﬁed
the extent of the decrease in proliferating cells using
dissociated retinae and found that the percentage of EdU-
positive cells was signiﬁcantly lower in Rb1/p107/Hells
TKO (0.076 ± 0.131%) compared with Rb1/p107 DKO
(1.22 ± 0.35%; p= 0.0064) retinae (Fig. 5h). Together,
these data suggest that HELLS overexpression (or per-
sistent expression) may contribute to the maintenance of
a de-differentiated and proliferative state in Rb1/p107-
null retinae that may result in retinoblastoma formation.
Discussion
In recent years, the chromatin remodeling protein
HELLS has been increasingly considered as a therapeutic
target in several cancers, including gliomas and carcino-
mas26,28,29. Our own studies, including this one, indicate
that HELLS might be an attractive target for retino-
blastoma therapeutics10. However, since HELLS is critical
for the survival of mice and is required for normal tissue
development, including the brain17, understanding the
function of HELLS during retinal development is relevant
if ocular delivery of HELLS inhibitors were to be con-
sidered as a therapeutic option for this retinal malignancy.
Fortunately, unlike a previous report showing that HELLS
mutant mice exhibit impaired neural progenitor cells self-
renewal and maintenance during development17, we show
in this study that Hells depletion does not affect RPC
(see ﬁgure on previous page)
Fig. 5 HELLS is necessary for ectopic proliferation in Rb1/p107-null retinae. a Principal components analysis (PCA) (2D loading plot) of RNA-seq
data from three Rb1/p107 DKO and three Rb1/p107/Hells TKO P21 retinae show distinct transcriptome clusters. b, c p value ranking bar graph
representing the ten most signiﬁcant gene ontology (GO) biological processes for (b) upregulated genes and (c) downregulated genes in Rb1/p107/
Hells TKO compared with Rb1/p107 DKO P21 retinae. d Genome-wide heatmap plot of chromatin accessibility peaks (ATAC-seq) from ﬂow-sorted
EGFP-negative Cre-negative Rb1/p107/Hells and EGFP-positive Rb1/p107 DKO and Rb1/p107/Hells TKO P21 retina grouped by mean reads and by
distance from the transcription starting site (TSS). Each row represents a gene ordered in descending accessibility mean reads. e Heatmap of all
differentially expressed genes GO clustered as G1/S transition of mitotic cell cycle in P21 retinae from Rb/p107 DKO compared with Rb1/p107/Hells
TKO mice. Highlighted in red are known genes transcriptionally co-activated by HELLS. f Real-time RT-qPCR validation of some of the RNA-seq
downregulated genes involved in cell cycle progression. n= 3; *p < 0.05 by unpaired t test. g Representative images of P21 retina cross-sections from
Rb1/p107 DKO and Rb1/p107/Hells TKO Z/EGmice labeled with Click-iT EdU (proliferating cells; red). Nuclei were counterstained with DAPI (blue). EGFP
ﬂuorescence by the Z/EG reporter transgene captured areas of Chx10-Cre-mediated EGFP expression (green). Images taken on ×20 power ﬁeld. Scale
bar= 50 μm. h Quantiﬁcation of the proportion of EdU-positive cells from dissociated retinae from Rb1/p107 DKO and Rb1/p107/Hells TKO mice from
independent litters (n= 3). Each bar represents the mean ± SD of 2000 cells scored from each retina. **p < 0.0021 by unpaired t test.
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division, cell-fate speciﬁcation, nor retinal function.
Despite the seemingly dispensable role of Hells in retinal
development, we found that persistent expression of Hells
in Rb1/p107-null retinal cells is critical for ectopic pro-
liferation and retinoblastoma tumor progression.
Hells is expressed during retinal cell-fate speciﬁcation
stages, but is nonessential for normal retinal development
Epigenetic regulation plays a fundamental role in the
maintenance of cell identity as well as the stepwise control
towards cellular differentiation. Here, we studied the role
of chromatin remodeler HELLS during retinal develop-
ment. We found that Hells mRNA is expressed in early
stages of retinal development and declines around post-
natal day 6. We conﬁrmed that this reduction in gene
expression translated into decreased protein expression.
These patterns of expression suggest that HELLS is
involved in the development and cell differentiation of the
retina, but is not necessary for maintenance of the retina
once the major cell types have developed.
We also assessed whether HELLS is critical for normal
retinal development using a conditional knockout mouse
model driven by Chx10-Cre recombinase. We found that
Hells-null mature (P21) retina display normal retinal cell
speciﬁcation and differentiation compared with their lit-
termate controls. This suggests that HELLS is either
unnecessary for retinal differentiation and development or
its loss of function is compensated by other chromatin
remodeling proteins.
The only difference we noted in Hells cKO retinae was a
modest abnormal lamination of bipolar cells when com-
pared with the surrounding Cre-negative tissue and lit-
termate controls. Bipolar cells are the last cell type to
terminally differentiate in the mouse retina, around
postnatal day 6 when Hells expression is seen to decrease
in the wild-type retina. It is possible that transcriptional
repression of Hells helps orchestrate bipolar cell migra-
tion such that when HELLS is not present, lamination of
bipolar cells is slightly altered. Despite this mild devel-
opmental defect, ERG measurements of the electrical
activity of the retina in response to light stimulation
indicated that Hells-null retina function is unaltered.
Hells is downregulated by Rb and p107 during late retinal
differentiation
Other groups and we have identiﬁed HELLS as a tran-
scriptional downstream target gene of E2F1 that is over-
expressed in cancer and contributes to tumor
progression9,10,30. The evidence of direct regulation of
HELLS by the RB family was limited to in vitro studies in
gliomas and osteosarcoma7,9. In this study, we conﬁrmed
that the RB/E2F signaling pathway directly regulates tran-
scriptional activation of HELLS in the developing retinae.
ChIP analysis revealed enrichment of E2F1 at a known
binding area on the promoter region of HELLS8 in retinal
tissue during early development or in the absence of Rb1/
p107. Interestingly, loss of Rb1, unlike humans, is insufﬁ-
cient to drive tumorigenesis in the developing murine
retina, nor does it exert Hells derepression during terminal
retinal differentiation. Our results show that in the murine
retinae, loss of both Rb1 and p107 are necessary for the
persistent expression of HELLS. These data suggest that the
compensation by p107 observed in the Rb1 cKO mouse
model is sufﬁcient to effectively repress Hells expression in
the absence of Rb1, an event that likely contributes to the
prevention of tumor formation in Rb1-null mice31. Since
HELLS expression levels during the early stages of retinal
development (E17.5 through P2) in Rb1/p107 DKO retinae
are comparable with those observed in wild-type retinae, it
is likely that the RB family is required for Hells repression
during terminal differentiation of one or several retinal cell
fates and failure to do so results in the aiding of tumor
progression.
HELLS overexpression is critical for proliferation and
retinoblastoma formation in Rb1/p107-null retina
In this study, we also sought to determine whether
HELLS plays a critical role during retinoblastoma devel-
opment. We found that HELLS abrogation during reti-
noblastoma development leads to a signiﬁcant decrease in
morbidity and increase in survival. The mechanism(s) by
which HELLS contributes to tumorigenesis, however,
remain unknown. One hypothesis is that HELLS over-
expression leads to increased de novo DNA methylation of
tumor suppressor genes, thereby decreasing the tran-
scriptional level of tumor suppressor genes and increasing
the incidence of tumor. Given the role of HELLS in
facultative heterochromatin formation, we found it intri-
guing that we did not observe signiﬁcant changes in gene
transcription in Rb1/p107/Hells TKO tumors compared
with Rb1/p107 DKO tumors. Given the absence of a ret-
inal phenotype upon loss of Hells, it is plausible that
compensation by other chromatin remodelers occurs
during retinal development, something that should be
explored in future studies. It is also interesting that more
than twice as many gene expression changes observed in
Rb1/p107/Hells TKO compared with Rb1/p107 DKO P21
retinae were gene downregulations and that these changes
were not associated with chromatin structure variations
and that global DNA methylation was unaltered upon
Hells loss.
Among the most signiﬁcantly downregulated transcripts in
Rb1/p107/Hells, TKO retinae are genes involved in cell cycle
regulation. As reﬂected by the normal functioning Hells cKO
retina, loss of Hells showed no signs of alterations in the
proliferation in retinal progenitor cells; however, we showed
that loss of Hells in Rb1/p107 differentiating retinae drasti-
cally reduced cellular proliferation. These in vivo results are
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in line with our previous observation in human retino-
blastoma cell lines, showing reduced proliferative capacity
upon HELLS knockdown10. There is a remarkable similarity
between the observations in this study and studies on the
E2F family. Activating E2Fs, (aE2Fs: E2F1/2/3) control the
transcription of genes required for DNA replication and
proliferation of quiescent cells, but are not required for
normal progenitor division in several tissues, including the
developing retina32–35. However, aE2Fs are essential for
abnormal division of differentiating RB-null cells32,34–36 and
removing E2F1 or E2F3 completely block retinoblastoma
formation10,37. Taken together, we propose that HELLS is a
critical downstream mediator of E2F-dependent ectopic
division in the Rb1/p107-null retina (Fig. 6). In the absence of
RB and p107, E2F1 transcriptional derepression drives the
expression of Hells. HELLS then functions as transcriptional
co-activator of E2F3, stimulating expression of growth pro-
moting genes during G1/S phase transitions27. The resulting
ectopic proliferation of differentiating retinal cells promotes
retinoblastoma formation.
The decrease in tumor burden and morbidity observed
in Rb1/p107/Hells TKO mice presents HELLS as an
attractive potential therapeutic target for the treatment of
retinoblastoma. This is particularly true given our obser-
vations indicating that HELLS expression is not essential
for normal retinal development and that HELLS is not
expressed in terminally differentiated retinal cells. This
suggests that ocular delivery of HELLS inhibitors might
reduce tumor burden with low retinal toxicities.
Materials and methods
The data discussed in this publication have been depos-
ited in NCBI’s Gene Expression Omnibus38 and are acces-
sible through GEO Series accession number GSE144429.
Mouse models
The Rblox/lox mice were obtained from the Mouse
Models of Human Cancer Consortium at the National
Cancer Institute; the p107−/− mice were obtained from
Dr. Tyler Jacks (Massachusetts Institute of Technology);
Chx10-Cre mice were obtained from Dr. Connie Cepko
(Harvard Medical School). Z/EG mice were obtained from
Dr. Itsuki Ajioka (Tokyo Medical and Dental University).
Hellslox/lox mice were obtained from the European Mouse
Mutant Archive, backcrossed to Flp mice for removal of
the neo-cassette (tm1c conversion), and then backcrossed
to C57BL/6N mice for ﬁnal Flp removal (Fig. 2a). All mice
are maintained in a C57BL/6N background, and both
sexes were used in the analysis. Mice were monitored
weekly, unblinded, for signs of retinoblastoma and ante-
rior chamber invasion for 1 year from the time of birth.
Moribund status was deﬁned as the point when tumor
cells invaded the anterior chamber and intraocular pres-
sure increased to the point of imminent ocular rupture.
The University of California Irvine Institutional Animal
Care and Use Committee approved all animal procedures.
Survival curves were generated using GraphPad Prism.
Mantel–Cox test was used for statistical analysis of the
Kaplan–Meier curves. Using trends from previous stu-
dies10, we have found that 20 mice per group were sufﬁ-
cient to accurately measure differences in survival with an
80% power at 0.05 signiﬁcance level in Rb1/p107/Hells
TKO compared with Rb1/p107 DKO mice.
Real-time reverse transcriptase PCR (RT-qPCR)
RNA was isolated from retinal tissue by homogenizing
samples using Trizol Reagent and then isolated using
chloroform. We used 1 µg of RNA to make cDNA
according to SuperScript™III First-strand synthesis
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Fig. 6 Model for HELLS function as driver of tumorigenesis in the developing retina. a In the normal developing retina, RB or p107 represses
E2F1 from driving HELLS expression by postnatal day 6 (P6). b In the absence of RB and p107, E2F1 drives Hells transcription beyond of P6. HELLS is
known to interact physically with E2F3 and function as transcriptional co-activator of E2F3. The resulting HELLS overexpression in the absence of RB
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system (Invitrogen) manufacturer’s protocol at a reaction
volume of 20 μl. Quantitative PCR ampliﬁcation was
performed using 1 µl of reverse-transcribed product in
Power SYBR Green PCR Master Mix (4367659, Life
Technologies). Reaction were carried out using 7500 Real-
Time PCR system (Applied Biosciences). Data were nor-
malized to endogenous 18S and GAPDH controls, and
analyzed using the ΔΔCt method. Primers used are listed
in Supplementary Table 1.
Western blotting
Retinae were homogenized by pellet pestle in RIPA
buffer (50mM Tris-HCl, pH= 8, 150mM NaCl, 1% NP-
40, 0.5% Sodium deoxycholate, 0.1% SDS, 1 mM EDTA)
with added protease inhibitor (Mini cOmplete™, Roche).
Samples were placed to lyse on ice for 30min and then
centrifuged at 14,000 rpm for 30 min at 4 °C. Assessed
protein concentration using the BCA protein assay
(Pierce™ BCA Protein Assay Kit). In all, 30 µg of the total
protein was used, and blot was run on SDS-PAGE gel
(Mini-PROTEAN, Bio-rad). The gel was then transferred
onto a PVDF membrane (Immobilon-P Membrane, EMD
Millipore) using a semi-dry transfer apparatus (Bio-rad).
The membrane was incubated in 3% nonfat dry milk
dissolved in tris-buffered saline (TBS) with 0.25% Tween
(TBS-T) at room temperature for an hour in order to
prevent nonspeciﬁc binding. Primary antibodies were
diluted in 0.5% nonfat dry milk in TBS-T as follows:
1:1000 anti-Hells (sc-28202, Santa Cruz Biotechnology),
1:2000 anti-tubulin (2144S, Cell Signaling Technology).
Membranes were incubated in primary antibody over-
night at 4 °C. The membranes were washed three times
with TBS-T for 5 min per wash then incubated with
corresponding secondary antibody for 30min at room
temperature. The secondary antibodies were prepared by
diluting in 0.5% nonfat dry milk in TBS-T as follows:
1:1000 peroxidase labeled anti-mouse IgG (PI-2000,
Vector Laboratories), 1:1000 peroxidase labeled anti-
rabbit IgG (PI-1000, Vector Laboratories). After incuba-
tion for 30min with secondary antibodies, the membranes
were again rinsed three times with TBS-T for 5 min per
wash. Bands were visualized using chemiluminescence
(SuperSignal™West Pico Chemiluminescent Substrate by
Thermo Scientiﬁc). Band intensity assessed using Image J
software.
Immunohistochemistry
Retinae were isolated in phosphate-buffered saline
(PBS) and ﬁxed overnight in 4% (w/v) paraformaldehyde.
Whole retinae were embedded in 4% (w/v) agarose in
PBS. The retinae were then cut into 50-μm slices using a
vibratome. Retinal sections were blocked in 5% (v/v)
normal donkey, goat, or rabbit serum, 0.5% Triton X-100
in PBS for 4 h at room temperature and then placed in
primary antibody in the same blocking solution at 4°
overnight. Mouse anti-calbindin antibody (C-9848,
Sigma) was used at 1:100, rabbit anti-recoverin antibody
(AB5585, Millipore) was used at 1:5000 dilution, mouse
anti-pH3 antibody (H6409, Sigma) was used at 1:200
dilution, mouse anti-syntaxin antibody (S0664, Sigma)
was used at 1:500 dilution, mouse anti-glutamine syn-
thetase (610518, BD Biosciences) was used at 1:100 dilu-
tion, rabbit anti-cone-arrestin antibody (AB15282,
Millipore) was used at 1:5000 dilution, and sheep anti-
chx10 antibody (X1180P, Exalpha Biological) was used at
1:200 dilution. The retinal sections were washed three
times with PBS and incubated in corresponding secondary
antibody diluted 1:500 in respective blocking buffer (goat,
rabbit, or donkey) for 1 h at room temperature in the
dark. Again, retinae were washed three times with PBS
and then incubated in 300 μl of Vectastain ABC kit
(Vector Laboratories) for 30 min at room temperature.
Retina washed three times in PBS, and then placed in
300 μL tyramide Cy3 1:125 in ampliﬁcation buffer (Perkin
Elmer) for 10min. Retinal sections were washed with PBS
three times, and DAPI was added (1:1000 dilution in PBS)
for 10min to stain the nuclei. Retina washed two times
with PBS, and mounted on slides. Imaging done using a
Zeiss Confocal microscope.
Immunocytochemistry of dissociated retina
Retina were isolated and dissociated using trypsin 100X
stock and incubation at 37 °C for 10 min. Trypsin inhi-
bitor and 1000X DNase I were added to sample and
incubated at 37 °C for 5 min. Complete culture medium
was then added, and cells were transferred to chamber
slides. The chamber slides were prepared with 1Xpoly-L-
lysine incubated for 5 min. Cells were allowed to incubate
on the slides for 30min at 37 °C. Then, media was aspi-
rated, and cells were ﬁxed using 4% (w/v) paraformalde-
hyde overnight at 4 °C. Slides washed with PBS twice.
Slides were then incubated with primary antibody over-
night at 4 °C. Mouse anti-calbindin antibody (C-9848,
Sigma) was used at 1:100, rabbit anti-recoverin antibody
(AB5585, Millipore) was used at 1:5000 dilution, mouse
anti-pH3 antibody (H6409, Sigma) was used at 1:200
dilution, mouse anti-syntaxin antibody (S0664, Sigma)
was used at 1:500 dilution, mouse anti-glutamine syn-
thetase (610518, BD Biosciences) was used at 1:100 dilu-
tion, rabbit anti-cone-arrestin antibody (AB15282,
Millipore) was used at 1:5000 dilution, and sheep anti-
chx10 antibody (X1180P, Exalpha Biological) was used at
1:200 dilution. Slides washed three times in PBS then
incubated with secondary antibody in 1:500 dilution with
the corresponding blocking buffer for 30min at room
temperature in the dark. Slides were washed three times
with PBS, and incubated in 300 μl of Vectastain ABC kit
(Vector Laboratories) for 30 min at room temperature.
Zocchi et al. Oncogenesis            (2020) 9:25 Page 12 of 15
Oncogenesis
Slides were washed three times in PBS and incubated with
tyramide Cy3 1:150 in ampliﬁcation buffer (Perkin Elmer)
for 10 min. After washing with PBS three times, DAPI was
added (1:1000 dilution in PBS) for 5 min to stain the
nuclei. Slides were washed twice with PBS and mounted
using gelvatol containing DABCO. Imaging was com-
pleted using Life Technologies EVOS microscope. Cell
scoring was performed by a blinded investigator.
Electroretinography (ERG)
For scotopic ERG measurement, mice were dark adap-
ted for 24 h prior to ERG recording. Each group consisted
of four 5-week-old mice. Under dim red light, mice were
anesthetized by intraperitoneal injection of a cocktail
consisting of 20 mg/ml ketamine and 5mg/ml xylazine in
phosphate-buffered saline at a dose of 0.1 ml per 20 g
body weight. Pupils were dilated with 1% tropicamide
(Henry Schein, Melville, NY), and applied with 2.5%
hypromellose (Akorn, Lake Forest, IL) to keep corneas
hydrated. Contact electrodes were placed on corneas
while the reference electrode needle was positioned sub-
dermally between the ears. The a-wave and b-wave
responses were recorded followed by a white light sti-
mulus of different ﬂash intensities (−3.3 to 1.7 log cd·s/m2).
For each intensity, 3–20 recordings were made with the
resting intervals for recovery from photobleaching and
were averaged for the ﬁnal amplitude. All ERGs were
recorded with the Celeris ophthalmic electrophysiology
system (Diagnosys LLC, Lowell, MA) and analyzed with
Espion V6 software (Diagnosys LLC). Statistical analysis
was performed with paired t test. Data are represented as
means ± SD. The investigator performing ERG measure-
ments was blinded to the mouse genotype.
Chromatin immunoprecipitation (ChIP assay)
ChIP assays were performed on Weri retinoblastoma
human cell line, postnatal day 0 retinae collected from wild-
type mice, or postnatal day 21 retinae collected from Rb1/
p107 DKO mice as previously described25. The antibodies
used for chromatin pull-down were anti-E2F1 (3742; Cell
Signaling) and rabbit IgG (sc-2027, Santa Cruz Bio-
technologies). ChIP DNA was analyzed by qPCR with SYBR
Green (Bio-Rad) in ABI-7500 (Applied Biosystems). Pri-
mers used are listed in Supplementary Table 1. The primers
ﬂank areas of homology in the mouse and human promoter
region locater between position −94 and 114 bp and −115
and −134 bp, respectively. In human, this sequence falls
within a functionally validated E2F1-binding region8. ChIP
experiments were run in triplicate for each of the three
independent retinal samples per condition (n= 3).
RNA sequencing
The total RNA was isolated using the RNA Micro Kit
(Qiagen). Subsequently, 500 ng of the total RNA was used
to create the RNA-seq library following the manu-
facturer’s protocol from puriﬁcation, mRNA fragmenta-
tion through the adenylation of end-repaired cDNA
fragments and cleanup (TruSeq Stranded mRNA, Illu-
mina). The collected sample was cleaned with AMPure
XP beads (Beckman Coulter) and eluted in 20 μl of
10 mM Tris buffer, pH 8, 0.1% Tween 20. A paired-end
100-bp sequencing run was performed on HiSeq 4000
yielding 348M PE reads with a ﬁnal library concentration
of 2 nM as determined by qPCR (KAPA Biosystem).
Sequencing reads were aligned to the mouse reference
genome (GRCm38, ENSEMBL v.92) using STAR
(v2.5.2a)39. Each read pair was allowed a maximum
number of mismatches of 10. Each read was allowed a
maximum number of multiple alignments of 3. Gene
counts for each sample were produced using HTSeq
(v0.6.1p1)40. Read count normalization and differential
expression analysis were performed using DESeq2
(v1.22.2) in R (v3.5.2)41. Genes with low reads (sum across
samples <10) were removed. Differentially expressed
genes (DEG) were calculated by comparing Rb1/p107/
Hells TKO to Rb1/p107 DKO, genes with base mean
≥10, Log2FoldChange ≥ 1 or ≤−1, and adjusted p value
(Benjamini–Hockberg) ≤ 0.05 were called differentially
expressed genes. 3D PCA plot was generated using the
R package plot3D (v1.1.1).
Chromatin proﬁling
Approximately 50,000 cells were harvested for ATAC-
seq for each replicate. Brieﬂy, retinae were dissociated, ﬂow
sorted into EGFP− or EGFP+ , assessed for cell viability,
counted, and washed with PBS. ATAC-seq was performed
as previously described42. ATAC-seq libraries were
sequenced with the Illumina HiSeq 4000 using 100 bp
paired-end single indexed run. Raw reads were ﬁrst QCed
(FASTQC) and quality and adapter trimmed using Trim-
momatic. Trimmed reads were then aligned to mm10 build
of the mouse genome using Bowtie2 (v2.2.5) with align-
ment parameters: bowtie2 -X 2000– local–dovetail.
Potential PCR duplicate reads were removed using Mark-
Duplicates from the Picard tools. Peaks were called in each
sample using MACS2 and further ﬁltered using the
ENCODE consensus blacklist regions (http://mitra.
stanford.edu/kundaje/akundaje/release/blacklists/mm10-
mouse/). Differential peaks were identiﬁed using R package
diffbind across the consolidated peak sets and metrics such
as adjusted p values were reported. Heatmap plot was
generated using deepTools3.
5-mC DNA dot blot
Genomic DNA was extracted from P21 retinae (Wizard SV
genomic DNA puriﬁcation Kit). Puriﬁed DNA was quanti-
ﬁed, sonicated, denatured, and transferred to the Nylon
membrane (RPN303B, GE Healthcare) according to the Cell
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Signaling DNA Dot Blot Protocol. 5methylcytosine (5-mC)
Ab (#28692, Cell Signaling) was used to detect global DNA
methylation of the samples. Methylene blue staining was
used to verify equal DNA loading across samples.
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